Advancing Life and Liberty Through Action

While any action will make an impact, comments reflecting unique perspectives are particularly powerful. As the federal government outlines, agencies “must respond to relevant and significant comments,” and “the perspective of individual persons” is especially valuable!

1. Federal fertility policy should begin with a simple principle: life begins at fertilization. Notably, the administration already recognizes this to at least some degree: The recent Embryo Adoption Awareness and Services grant opportunity issued by the Office of Population Affairs (OPA) “recognizes embryo adoption first and foremost as a response to the needs of children who already exist and are in need of a family.”
2. As outlined by Maureen Condic, Ph.D., associate professor of neurobiology at the University of Utah School of Medicine, “The conclusion that human life begins at sperm-egg fusion is uncontested, objective, based on the universally accepted scientific method of distinguishing different cell types from each other and on ample scientific evidence. ... Moreover, it is entirely independent of any specific ethical, moral, political, or religious view of human life or of human embryos." Hence, the federal government needs to ensure robust protections for embryonic life in any official action related to ART, including this proposed excepted fertility benefit.
3. Infertility must be clearly classified as a medical condition – not a lifestyle choice. Any rule on this matter should clearly define infertility as a clinical condition that presents with the symptom of inability to conceive or sustain a pregnancy that points to underlying male and/or female pathology. Treatment and related coverage options should therefore be centered on addressing underlying causes of infertility.
4. Coverage under the proposed excepted fertility benefit should be limited to restorative practices, which are far more effective in promoting holistic health care than assisted reproductive technologies like IVF, and far less expensive. If IVF coverage remains an option under the proposed rule, patients should first be informed about and offered restorative reproductive care so that less invasive, less expensive, and potentially more effective treatments are prioritized rather than overlooked.
5. If the proposed rule includes IVF coverage, clinics receiving reimbursement should be required to implant all embryos created (by default this prohibits embryo destruction and research). Such clinics should also be required to report embryo losses, adverse events, negligence claims, success rates, lawsuits, and long-term health outcomes. Taxpayers and patients deserve transparency.
6. As millions of embryos remain frozen in storage across the United States, any policy that expands access to IVF should address the growing frozen-embryo crisis by promoting ethical embryo adoption programs and prohibiting the creation of embryos without a clear plan for implantation.
7. Federal policy must prioritize solutions that treat the cause of infertility, not merely the symptom. Too many couples are directed toward IVF before receiving a thorough evaluation for conditions such as endometriosis, PCOS, hormonal disorders, male-factor infertility, or other underlying health conditions that may be treatable. The rule should ensure patients receive care that diagnoses and treats such underlying conditions.
8. Restorative Reproductive Medicine (RRM) offers a more patient-centered approach by identifying and treating root causes of infertility. One study reports a live-birth rate ranging from 29% to 66% for subfertile couples who undergo “Restorative Reproductive Medicine ... for up to two years.” RRM can also help couples who previously experienced failed IVF cycles achieve live-birth.
9. IVF is extraordinarily expensive. Couples often spend $15,000 to $30,000 per cycle and may require multiple cycles before achieving a successful birth. In contrast, restorative approaches are frequently less costly—under $10,000—and also improve broader reproductive health.
10. Before federal policy subsidizes additional IVF procedures, it should prioritize less invasive, lower-cost, and medically restorative treatments that can help couples conceive while improving long-term reproductive health outcomes, which are better for mom and baby.
11. Many Americans are unaware that alternatives to IVF exist. A recent analysis of public opinion polls shows 70% of patients prefer treatments that address underlying causes, and that when patients learn about treatments that address the root causes of infertility, they strongly prefer those options over laboratory fertilization.
12. Nearly half of surveyed individuals were unaware of the medical risks associated with IVF, demonstrating a significant informed-consent gap. Patients deserve full and accurate information regarding risks, success rates, costs, and alternative treatments before making life-altering decisions.
13. Endometriosis illustrates why root-cause medicine matters. It is present in a substantial percentage of unexplained infertility cases, often takes seven to nine years to diagnose, and is associated with increased miscarriage risk. Women should not be routed directly to IVF when conditions like this may be contributing to infertility – especially as failure to address them increases miscarriage risk during IVF.
14. Fertility clinics have experienced freezer failures affecting thousands of embryos and hundreds of families. Families have also experienced devastating embryo mix-ups that resulted in parents unknowingly carrying, giving birth to, and in some cases surrendering another couple's biological child. No family seeking fertility treatment should ever face such tragedies. These events demonstrate the need for stronger accountability and safety requirements before expanding federal support for IVF.
15. The fertility industry operates with surprisingly limited oversight compared to most other areas of medicine. Existing reporting requirements are fragmented and often fail to capture critical adverse outcomes like putting the wrong sperm in the wrong egg, embryo mix-ups, laboratory failures, and other serious mistakes. If IVF is to be included under the proposed rule, reimbursement to clinics should be conditioned on strong safeguards, including:
Absent such protections, expanding IVF access risks amplifying the many problems that currently plague the fertility industry.
16. I fully support the voluntary nature of the proposed rule, which is critical to maintain robust freedom of conscience protection. In addition, individuals seeking to opt-in to an employer plan covering both RRM and assisted reproductive technologies like IVF should be able to opt-out of subsidizing IVF coverage through their premiums.
17. Evidence shows that assisted reproductive technologies lead to increased risks of preterm birth, low birth weight, birth defects, stillbirth, and other adverse outcomes (see Liberty Counsel Action's white paper, "Current Fertility Industry Practices Call for Strict Oversight, Promotion of Restorative Reproductive Medicine"). These risks should be disclosed to any couples seeking IVF under the proposed excepted fertility benefit.
18. Research shows heightened pregnancy risks for women undergoing assisted reproductive technologies, reinforcing the need to exhaust less invasive options before proceeding to IVF. (See Liberty Counsel Action's white paper, "Current Fertility Industry Practices Call for Strict Oversight, Promotion of Restorative Reproductive Medicine" for more on this.)
19. Expanding IVF access alone is unlikely to solve America's fertility challenges. Indeed, research indicates that state IVF insurance mandates do not increase birth rates, suggesting expanding access to IVF is an ineffective policy option if the goal is (at least in part) an increased birth rate.
20. To be eligible for reimbursement under the proposed rule, IVF clinics should be subject to routine inspections, meaningful certification standards, mandatory reporting of adverse events, and enforceable oversight mechanisms. No other area of medicine would tolerate the level of self-regulation currently found in much of the fertility industry. Likewise, uniform informed-consent requirements should be mandatory. Patients should receive clear disclosures regarding success rates, miscarriage risks, costs, alternative treatments, and potential health risks to both mother and child.